- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05394116
L'examen de l'innocuité et de l'efficacité du garetosmab par rapport au placebo administré par voie intraveineuse (IV) chez les participants adultes atteints de fibrodysplasie ossifiante progressive (FOP) (OPTIMA)
Étude de phase 3 randomisée et contrôlée par placebo pour évaluer l'innocuité, la tolérabilité et l'efficacité du garétosmab chez les patients atteints de fibrodysplasie ossifiante progressive
This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP).
The aim of the study is to see how safe and effective the study drug is in patients with FOP.
The study is looking at several other research questions, including:
- What side effects may happen from receiving the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Cape Town
-
Rondebosch, Cape Town, Afrique du Sud, 7700
- University of Cape Town
-
-
-
-
New South Wales
-
St Leonards, New South Wales, Australie, 2065
- Royal North Shore Hospital
-
-
-
-
-
São Paulo, Brésil, 05652-900
- Hospital Israelita Albert Einstein
-
-
-
-
Biobio
-
Concepción, Biobio, Chili, 4030000
- Universidad de Concepcion
-
-
-
-
-
Shanghai, Chine, 200065
- Tongji Hospital of Tongji University
-
-
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombie, 140013
- Clinica Universidad de La Sabana
-
-
-
-
-
Seoul, Corée du Sud, 03080
- Seoul National University Hospital
-
-
-
-
-
Madrid, Espagne, 28034
- Hospital Universitario Ramon y Cajal
-
-
-
-
Stenbäckinkatu 11
-
Helsinki, Stenbäckinkatu 11, Finlande, 00029
- HUS Children and Adolescents Park Hospital Clinical Trial Unit
-
-
-
-
-
Montpellier, France, 34090
- Hôpital Lapeyronie
-
Paris, France, 75010
- Hopital Lariboisiere
-
-
-
-
-
Hong Kong, Hong Kong, 22553838
- Queen Mary Hospital
-
-
-
-
-
Genoa, Italie, 16147
- IRCCS Istituto Giannina Gaslini
-
-
-
-
-
Fukuoka, Japon, 812-8582
- Kyushu University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 466-8560
- Nagoya University Hospital
-
-
Oita Prefecture
-
Yufu, Oita Prefecture, Japon, 879-5593
- Oita University Hospital
-
-
-
-
-
Kuala Lumpur, Malaisie, 50586
- Hospital Kuala Lampur
-
-
-
-
North Holland
-
Amsterdam, North Holland, Pays-Bas, 1081 HV
- Amsterdam University Medical Center
-
-
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Pologne, 35-326
- Szpital Centrum Medyczne Medyk
-
-
-
-
Greater London
-
Middlesex, Greater London, Royaume-Uni, HA7 4LP
- Royal National Orthropaedic Hospital NHS Trust
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- University of California Los Angeles (UCLA) Medical Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Clinical diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) [(based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive Heterotopic Ossification (HO)]
- Confirmation of FOP diagnosis with documentation of Type I activin A receptor (ACVR1) FOP causing mutation
- FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, or other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of HO lesions (increase in size or number of HO lesions) with/without being associated with flare-up episodes
- Willing and able to undergo CT imaging procedures and other procedures as defined in the protocol
Key Exclusion Criteria:
-
Cumulative Analog Joint Involvement Scale (CAJIS) score at screening >19
-
Participant has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
-
Previous history or diagnosis of cancer
-
Severely impaired renal function defined as estimated glomerular filtration rate <30 milliliter per minute (mL/min) (/1.73 m^2 calculated by the Modification of Diet in Renal Disease equation
-
Uncontrolled diabetes defined as hemoglobin A1C (HbA1c) >9% at screening
-
History of poorly controlled hypertension, as defined by:
- Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at the screening visit
- Systolic blood pressure of 160 mm Hg to 179 mm Hg or diastolic blood pressure of 100 mm Hg to 10^9 mm Hg at the screening visit, AND a history of end-organ damage (including history of left-ventricular hypertrophy, heart failure, angina, myocardial infarction, stroke, transient ischemic attack, peripheral arterial disease, end-stage renal disease, and moderate-to-advanced retinopathy
-
Known history of cerebral vascular malformation
-
Cardiovascular conditions such as New York Heart Association class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia
-
History of severe respiratory compromise requiring oxygen, respiratory support (eg, bilevel positive airway pressure [biPAP] or continuous positive airway pressure [CPAP]), or a history of aspiration pneumonia requiring hospitalization
-
Prior use in the past year and concomitant use of bisphosphonates
-
Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures (eg, collection of blood or tissue samples)
-
Treatment with another investigational drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer
-
Pregnant or breastfeeding women
-
Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception, as defined in the protocol
-
Male patients with WOCBP partners who are not willing to use condoms with WOCBP partners to prevent potential fetal exposure, as defined in the protocol
Note: Other protocol defined Inclusion/Exclusion Criteria apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: High dose Garetosmab
Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W) |
Garetosmab is supplied as a liquid drug product and will be administered IV.
Autres noms:
|
|
Expérimental: Low dose Garetosmab
Garetosmab is administered by IV administration Q4W |
Garetosmab is supplied as a liquid drug product and will be administered IV.
Autres noms:
|
|
Expérimental: Placebo
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W. |
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of New Heterotopic Ossification (HO) Lesions
Délai: Week 56
|
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by computed tomography (CT) that developed after baseline. This endpoint represents the cumulative number of New HO Lesions across all participants. |
Week 56
|
|
Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)
Délai: Baseline up to Week 56 [to include participants who discontinued earlier]
|
The following were considered AESIs:
|
Baseline up to Week 56 [to include participants who discontinued earlier]
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Clinician-assessed Flare-ups
Délai: Baseline through Weeks 28 and 56
|
Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. This endpoint represents the cumulative number of Clinician-assessed Flare-ups across all participants. |
Baseline through Weeks 28 and 56
|
|
Number of Participants With New HO Lesions at Weeks 28 and 56
Délai: Weeks 28 and 56
|
Reported as Yes/No The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline. |
Weeks 28 and 56
|
|
Total Volume of New HO Lesions
Délai: Weeks 28 and 56
|
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline. |
Weeks 28 and 56
|
|
Percentage of Participants With Participant-reported Flare-ups
Délai: Baseline through Weeks 28 and 56
|
Reported as Yes/No |
Baseline through Weeks 28 and 56
|
|
Number of New HO Lesions
Délai: Week 28
|
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline. |
Week 28
|
|
Percentage of Participants With Clinician-assessed Flare-ups
Délai: Baseline through Weeks 28 and 56
|
Reported as Yes/No |
Baseline through Weeks 28 and 56
|
|
Number of Participant-reported Flare-ups
Délai: Baseline through Weeks 28 and 56
|
Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily. This endpoint represents the cumulative number of Participant-reported Flare-ups across all participants. |
Baseline through Weeks 28 and 56
|
|
Change From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)
Délai: Baseline, Weeks 28 and 56
|
CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30 |
Baseline, Weeks 28 and 56
|
|
Change in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry
Délai: Baseline, Weeks 28 and 56
|
Forced expiratory volume in 1 second (FEV1) will be determined by spirometry. |
Baseline, Weeks 28 and 56
|
|
Change From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)
Délai: Baseline, Weeks 28 and 56
|
PGIS is a single item, self-administered questionnaire to assess the participant's global impression of severity. PGIS scores range from 0 to 4 ([0]: none, [1]: mild, [2]: moderate, [3]: severe, [4]: very severe). LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect and the baseline value as continuous covariate |
Baseline, Weeks 28 and 56
|
|
Patient's Global Impression of Change (PGIC) Scale Score
Délai: Weeks 28 and 56
|
PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change. The PGIC scale uses a 7-point rating format where participants select the response that best describes how their condition has changed: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect. |
Weeks 28 and 56
|
|
Clinician's Global Impression of Change (CGIC) Scale Score
Délai: At Weeks 28 and 56
|
CGIC is a single-item questionnaire to assess the clinician's global impression of change. The clinician assessed the participant's condition and scored the change using the following standard 7-point scale: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect. |
At Weeks 28 and 56
|
|
Concentration of Total Activin A in Serum Over Time
Délai: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
|
Concentrations below the lower limit of quantitation (LLOQ) (0.000313 milligrams [mg]/L) were set to 0. |
Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
|
|
Concentration of Garetosmab in Serum Over Time
Délai: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
|
Concentrations below the LLOQ (0.078 mg/L) were set to 0. |
Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
|
|
Number of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time
Délai: Baseline through Week 56
|
Baseline through Week 56
|
|
|
Number of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56
Délai: Baseline through Week 56
|
Baseline through Week 56
|
|
|
Number of Clinician-assessed Flare-ups at Week 84
Délai: Through Week 84
|
Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. Week 84 Only for Patients on Extended Treatment |
Through Week 84
|
|
Percentage of Participants With New HO Lesions at Week 84
Délai: At Week 84
|
Reported as Yes/No Week 84 Only for Patients on Extended Treatment |
At Week 84
|
|
Total Volume of New HO Lesions
Délai: At Week 84
|
Week 84 Only for Patients on Extended Treatment |
At Week 84
|
|
Number of New HO Lesions
Délai: At week 84
|
Week 84 Only for Participants on Extended Treatment |
At week 84
|
|
Percentage of Participants With Clinician-assessed Flare-ups
Délai: Through Week 84
|
Reported as Yes/No Week 84 Only for Participants on Extended Treatment |
Through Week 84
|
|
Change in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry
Délai: Baseline, Weeks 28 and 56
|
FVC will be determined by spirometry. |
Baseline, Weeks 28 and 56
|
|
Change in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry
Délai: Baseline, Weeks 28 and 56
|
The ratio of FEV1/FVC will be determined by spirometry. |
Baseline, Weeks 28 and 56
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trial Management, Regeneron Pharmaceuticals
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- R2477-FOP-2175
- 2022-000880-40 (Identificateur de registre: EudraCT)
- 2023-508350-26-00 (Identificateur de registre: CTIS (EU))
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Délai de partage IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Critères d'accès au partage IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .